Aventis Submits Taxotere sNDA In Early-Stage Breast Cancer; Two More Planned By Early 2005

The filing is the second of four supplements planned for the oncologic over the next year. A prostate cancer sNDA was submitted earlier in the year; filings for gastric cancer and head and neck cancer are expected.